Traws Pharma, Inc. (NASDAQ: TRAW) reported its financial results for the quarter ended September 30, 2026, in a filing dated November 16, 2026. The company, which focuses on developing therapies for COVID-19 and influenza, provided updates on its clinical-stage programs and disclosed its balance sheet and operating expenses for the period.

Regarding its antiviral pipeline, the company highlighted progress on two key candidates. For ratutrelvir, a once-daily oral antiviral for COVID-19, the final Phase 2a results were announced. The study involved 92 subjects and showed symptom resolution comparable to PAXLOVID, with a median time to sustained symptom resolution of 13.5 days for ratutrelvir versus 14.5 days for PAXLOVID in eligible subjects. The company noted that treatment-related adverse events occurred in 1 of 32 ratutrelvir-treated patients compared to 4 of 30 treated with PAXLOVID. In a cohort of 30 PAXLOVID-ineligible subjects, the median symptom resolution was 14.0 days with no adverse events reported. Traws intends to discuss a registration strategy with the FDA focused on high-risk patients ineligible for PAXLOVID.

For tivoxavir marboxil (TXM), an investigational agent for influenza prevention, the company reported the successful completion of a tablet bridging study. The compressed-tablet formulation provided exposure comparable to the powder-in-capsule formulation and was well tolerated. Toxicology retesting was also completed, and the company expects to resubmit the updated toxicology package in the fourth quarter of 2026.

On the corporate front, Traws entered into a $50 million common stock purchase agreement with Roth Principal Investments on October 23, 2026. Under this agreement, the company has the right, but not the obligation, to sell up to $50 million of its common stock to Roth, subject to customary conditions. As of November 13, 2026, no shares have been sold under this agreement.

The company’s financial results for the third quarter of 2026 showed cash and cash equivalents of $2.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025. Research and development expenses for the quarter were $1.8 million, compared to $2.3 million in the prior year. General and administrative expenses were $1.8 million for the third quarter of 2026, compared to $1.7 million in the prior year. The net loss for the quarter was $3.5 million, or $0.18 per share, compared to a net loss of $4.0 million, or $0.34 per share, in the prior year.

As of September 30, 2026, Traws had 15,368,277 shares of common stock outstanding. Total assets were reported at $7.5 million, with total liabilities and stockholders' deficit at $7.5 million.